Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Remdesivir

FDA-approved product (powder, intravenous), marketed as Veklury.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Remdesivir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Coronavirus infectious disease
  • COVID-19
  • Severe acute respiratory syndrome
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
FDA pharmacologic class
SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB16

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Remdesivir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Remdesivir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

    NCT05780463 · start 2021-06-11

    Registered record
    Registry ID
    NCT05780463
    Conditions
    COVID-19
    Interventions
    MP0420; Placebo; Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-11
    Completion
    2023-06-08
    Enrolment
    485

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionMP0420; Placebo; Remdesivir
    PhasePhase 3
    Registry statusCompleted

  • Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

    NCT04784559 · start 2021-06-04

    Registered record
    Registry ID
    NCT04784559
    Conditions
    COVID-19 Infection
    Interventions
    Plitidepsin; Dexamethasone; Remdesivir; Favipiravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-06-04
    Completion
    2023-03-01
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Infection
    InterventionPlitidepsin; Dexamethasone; Remdesivir; Favipiravir
    PhasePhase 3
    Registry statusTerminated

  • World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments

    NCT04647669 · start 2021-06-01

    Registered record
    Registry ID
    NCT04647669
    Conditions
    Covid19
    Interventions
    Remdesivir; Acalabrutinib; Interferon beta-1a; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-06-01
    Completion
    2021-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionRemdesivir; Acalabrutinib; Interferon beta-1a; Standard of Care
    PhasePhase 3
    Registry statusUnknown

  • Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study

    NCT04904783 · start 2021-06-01

    Registered record
    Registry ID
    NCT04904783
    Conditions
    COVID-19; Pneumonia
    Interventions
    Low dose radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-06-01
    Completion
    2021-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19; Pneumonia
    InterventionLow dose radiotherapy
    PhaseNot applicable
    Registry statusUnknown

  • Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

    NCT04672564 · start 2021-03-30

    Registered record
    Registry ID
    NCT04672564
    Conditions
    Coronavirus Disease 2019
    Interventions
    Carrimycin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-03-30
    Completion
    2022-05-09
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Disease 2019
    InterventionCarrimycin; Placebo
    PhasePhase 3
    Registry statusTerminated

  • SARS-CoV-2 Human Challenge Characterisation Study

    NCT04865237 · start 2021-03-06

    Registered record
    Registry ID
    NCT04865237
    Conditions
    Covid19; SARS-CoV Infection; Corona Virus Infection; Coronavirus; COVID-19
    Interventions
    SARS-CoV-2 Virus 1x10^1 TCID50; Remdesivir; SARS-CoV-2 Virus 1x10^2 TCID50; SARS-CoV-2 Virus 1x10^3 TCID50
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-03-06
    Completion
    2022-07-11
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS-CoV Infection; Corona Virus Infection; Coronavirus +1 more
    InterventionSARS-CoV-2 Virus 1x10^1 TCID50; Remdesivir; SARS-CoV-2 Virus 1x10^2 TCID50; SARS-CoV-2 Virus 1x10^3 TCID50
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients

    NCT04713176 · start 2021-02-02

    Registered record
    Registry ID
    NCT04713176
    Conditions
    Severe COVID-19
    Interventions
    DWJ1248 with Remdesivir; Placebo with Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-02-02
    Completion
    2022-12-09
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere COVID-19
    InterventionDWJ1248 with Remdesivir; Placebo with Remdesivir
    PhasePhase 3
    Registry statusTerminated

  • Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip

    NCT04980534 · start 2021-01-08

    Registered record
    Registry ID
    NCT04980534
    Conditions
    Covid19; COVID-19 Pneumonia; COVID-19 Respiratory Infection; Viral Infection; Respiratory Tract Infections; Infection, Coronavirus; SARS-CoV2 Infection
    Interventions
    Viusid and Asbrip; COVID-19 Standard Therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-01-08
    Completion
    2021-09-15
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; COVID-19 Pneumonia; COVID-19 Respiratory Infection; Viral Infection +3 more
    InterventionViusid and Asbrip; COVID-19 Standard Therapy
    PhaseNot applicable
    Registry statusCompleted

  • First-in-Human Study of Orally Administered GS-441524 for COVID-19

    NCT04859244 · start 2021-01-01

    Registered record
    Registry ID
    NCT04859244
    Conditions
    COVID-19
    Interventions
    GS-441524
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2021-08-01
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionGS-441524
    PhasePhase 1
    Registry statusCompleted

  • Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

    NCT05279391 · start 2020-10-25

    Registered record
    Registry ID
    NCT05279391
    Conditions
    COVID-19 Severe Respiratory Failure
    Interventions
    Dexamethasone; Low molecular weight heparin; Anakinra 100Mg/0.67Ml Inj Syringe; Tocilizumab; Baricitinib; Dornase Alfa Inhalant Product
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-10-25
    Completion
    2023-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Severe Respiratory Failure
    InterventionDexamethasone; Low molecular weight heparin; Anakinra 100Mg/0.67Ml Inj Syringe; Tocilizumab +2 more
    PhaseNot applicable
    Registry statusUnknown

  • ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

    NCT04583956 · start 2020-10-23

    Registered record
    Registry ID
    NCT04583956
    Conditions
    COVID-19
    Interventions
    Placebo; Remdesivir; Risankizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-10-23
    Completion
    2021-09-13
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionPlacebo; Remdesivir; Risankizumab
    PhasePhase 2
    Registry statusCompleted

  • Immune Modulators for Treating COVID-19

    NCT04593940 · start 2020-10-15

    Registered record
    Registry ID
    NCT04593940
    Conditions
    Covid19
    Interventions
    Infliximab; Abatacept; Remdesivir; cenicriviroc (closed to enrollment as of 3-Sep-2021)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-10-15
    Completion
    2022-03-05
    Enrolment
    1,971

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionInfliximab; Abatacept; Remdesivir; cenicriviroc (closed to enrollment as of 3-Sep-2021)
    PhasePhase 3
    Registry statusCompleted

  • REMdesivir-HU Clinical Study and Severe Covid-19 Patients

    NCT04610541 · start 2020-10-12

    Registered record
    Registry ID
    NCT04610541
    Conditions
    SARS-CoV-2 Infection
    Interventions
    Remdesivir-HU
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-10-12
    Completion
    2021-11-30
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSARS-CoV-2 Infection
    InterventionRemdesivir-HU
    PhasePhase 3
    Registry statusUnknown

  • Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

    NCT04546581 · start 2020-10-08

    Registered record
    Registry ID
    NCT04546581
    Conditions
    COVID; COVID-19; SARS-CoV-2; SARS (Severe Acute Respiratory Syndrome)
    Interventions
    Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG); Placebo; Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-10-08
    Completion
    2021-05-21
    Enrolment
    593

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID; COVID-19; SARS-CoV-2; SARS (Severe Acute Respiratory Syndrome)
    InterventionHyperimmune immunoglobulin to SARS-CoV-2 (hIVIG); Placebo; Remdesivir
    PhasePhase 3
    Registry statusCompleted

  • Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

    NCT04480333 · start 2020-09-15

    Registered record
    Registry ID
    NCT04480333
    Conditions
    Covid19; Corona Virus Infection; Severe Acute Respiratory Syndrome; Severe Acute Respiratory Infection; Severe Acute Respiratory Syndrome (SARS) Pneumonia; Severe Acute Respiratory Syndrome of Upper Respiratory Tract; Neurodegeneration; Neuroinflammatory Response
    Interventions
    Drug: NA-831 - 0.10 mg/kg; Placebo- 0.10 mg/kg; Drug: NA-831 - 0.20 mg/kg; Placebo- 0.20 mg/kg; Drug: GS-5734 - 1.00 mg/kg; Placebo- 1.00 mg/kg; Drug: GS-5734 - 2.00 mg/kg; Placebo- 2.00 mg/kg; Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg); Placebo 0.10 mg + 1.00 mg/kg; Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg); Placebo 0.20 mg + 2.00 mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2020-09-15
    Completion
    2021-03-31
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; Corona Virus Infection; Severe Acute Respiratory Syndrome; Severe Acute Respiratory Infection +4 more
    InterventionDrug: NA-831 - 0.10 mg/kg; Placebo- 0.10 mg/kg; Drug: NA-831 - 0.20 mg/kg; Placebo- 0.20 mg/kg +8 more
    PhasePhase 1
    Registry statusUnknown